24 news items
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
BPMC
30 May 24
/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
BPMC
23 May 24
. Dejan Duric from the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital
Unveiling 18 Analyst Insights On Blueprint Medicines
BPMC
14 May 24
1
In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting
Stephens & Co. Initiates Coverage On Blueprint Medicines with Overweight Rating, Announces Price Target of $140
BPMC
14 May 24
Stephens & Co. analyst Sudan Loganathan initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Overweight rating and announces Price Target of $140.
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BPMC
6 May 24
and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug
6p7uwkwmtwfisq6ccx02w6rbi24qj
BPMC
6 May 24
(NASDAQ:BPMC) from Underperform to Market Perform and raises the price target from $50 to $97.
v2su7
BPMC
6 May 24
Goldman Sachs analyst Terence Flynn maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $121 to $168.
l1pm2tn3duypwrx l7bqu
BPMC
3 May 24
Citigroup analyst David Lebowitz maintains Blueprint Medicines (NASDAQ:BPMC) with a Sell and raises the price target from $65 to $76.
gdrmgpnp cm1jnjitpttcj5cwtrtmwn45mouokeucfs4p96vs1n3
BPMC
3 May 24
HC Wainwright & Co. analyst Andrew Fein maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $125 to $135.
i7p5gcthz7hwj
BPMC
3 May 24
JMP Securities analyst Reni Benjamin maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and raises the price target from $114 to $125.
cks0821b1nqddt
BPMC
3 May 24
Barclays analyst Peter Lawson maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and raises the price target from $70 to $75.
ot5oesscwp2lph0ngf0l3opi2q9srmeuddla7vsdndplmgv2kfugk7nqnm1q
BPMC
3 May 24
Piper Sandler analyst Christopher Raymond maintains Blueprint Medicines (NASDAQ:BPMC) with a Neutral and raises the price target from $78 to $104.
y7en128sc39ckiyt4 edsonunj3lp5f9k2bdt3fxjcdd3ycm
BPMC
3 May 24
Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $97 to $130.
qniqwbwahj6c1fae6wk1rnyj3cf75poqx84zlnijwtkxid42lywmfsevaj
BPMC
2 May 24
Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $97 price target.
r79h58h8eputhydk j5g80tpao
BPMC
2 May 24
mast cell-targeted therapies to address large medical needs in allergy and inflammation. The company plans to host additional educational webcasts
mccmk2qyrb6d2q5ktwn6yizkx3n51
BPMC
26 Apr 24
Stifel analyst Bradley Canino maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $120 to $130.
ffwreqmiy6l4rrftuxnb5sus1urhlg 1te4fi9wlyblec2
BPMC
26 Apr 24
Wedbush analyst David Nierengarten reiterates Blueprint Medicines (NASDAQ:BPMC) with a Outperform and maintains $110 price target.
5trtm5nj8i0xsrjbx16y9b8vgcmqgf7vois0iuha
BPMC
26 Apr 24
HC Wainwright & Co. analyst Andrew Fein reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $125 price target.
j4su1e8nfmtwojjnyp gaz
BPMC
26 Apr 24
Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $97 price target.
39o9 xgxf
BPMC
11 Apr 24
cell diseases, will join members of Blueprint Medicines' management team to provide a perspective on the mast cell as a promising target for treating